Home > Boards > US OTC > Biotechs >

Innovus Pharmaceuticals Inc. (INNV)

Add INNV Price Alert      Hide Sticky   Hide Intro
Moderator: Drugdoctor, kkpennies, Honeycomb777, gi197845, florida investor
Search This Board: 
Last Post: 4/21/2019 7:49:00 AM - Followers: 155 - Board type: Free - Posts Today: 3


*32 Products in USA / 12 Internationally*

 www.innovuspharma.com (Website)


* shareholders, please consider purchasing product(s)

 2018 Net Revenue Guidance of ~$23M (Up from $8.8M in 2017)


Innovus Pharma Launches FlutiCare OTC Nasal Spray Allergy Relief in the U.S. Press Release |11/14/2017

Innovus Pharmaceuticals, Inc. (“Innovus Pharma” or the “Company”) (OTCQB Venture Market: INNV), an emerging commercial-stage pharmaceutical company that delivers safe, innovative and effective over-the-counter (“OTC”) medicine and consumer care products to improve men’s and women's health and respiratory diseases, today announced that it has officially launched FlutiCare™ OTC in the U.S. FlutiCare™ contains the most prescribed nasal steroid active pharmaceutical ingredient (“API”) and form for nasal allergy relief over the last 7 years. The Company is launching FlutiCare™ in over 10,000 independent pharmacies, direct and through Amerisource Bergen and McKesson, via its Beyond Human® extensive print media platform and through its extensive online channels and distributors, including its own website, Amazon, and Walmart online stores. As a second phase of its launch, Innovus Pharma will launch FlutiCare™ to large retail stores.

FlutiCare™ will be available OTC with the same prescription strength and same delivery method as Flonase®* and ClariSpray®*. The Company currently believes that FlutiCare™ will be the most affordable fluticasone propionate nasal spray on the market and is now available in one dose, a 30 Day (120 Sprays) treatment and is the only one providing an monthly autoship plan.

“We are very excited to launch FlutiCare™ OTC and provide all patients with allergy relief,” stated Dr. Bassam Damaj, President and Chief Executive Officer of Innovus Pharma. “FlutiCare™ traces its roots as the most prescribed Rx 24-hour nasal allergy spray API and form in the U.S. over the past 7 years by a factor of over 10 to 1,” he continued.

FlutiCare™ was approved by the U.S. Food and Drug Administration (“FDA”) for OTC availability through Innovus Pharma’s partner’s approved abbreviated new drug application (“ANDA”) No. 207957. FlutiCare™ allergy relief joins the growing Innovus Pharma product family, offering a burgeoning portfolio of non-prescription medicine and consumer care supplements to consumers.

FlutiCare™ becomes the Company’s second available allergy relief product along with AllerVarx™, a patented dietary supplement formulated to provide relief during the allergy season, already on the market.

In addition, the Company, pending FDA’s guidance, plans to move forward with a fluticasone kit for nasal allergy containing FlutiCare™ and our upcoming saline nasal spray NasaVa™.

About FlutiCare™

FlutiCare™ is a nasal spray, which provides 50 micrograms of fluticasone propionate (“USP”) per spray, a nasal corticosteroid that provides 24-hour temporary relief of seasonal and perennial nasal allergy symptoms. FlutiCare™ can be used to relieve both indoor and outdoor nasal allergy symptoms caused by pollen, dust, animal dander, and other indoor and outdoor allergens. Nasal allergy symptoms include, nasal congestion, runny nose, sneezing, itchy nose, etc.

** FlutiCare contains the nasal steroid API that is physician recommended and consumer preferred **

  • #1 form used by patients;
    #1 nasal steroid active prescribed by physicians;
    Familiar to patients, comfort of a known & trusted medicine;
    Engrained in patients’ allergy management; and
    Effective and safe.



Company Profile:

Headquartered in San Diego, Innovus Pharma is an emerging leader in OTC and consumer products for men's and women's health and vitality. The Company generates revenues from its lead products (a) BTH® Testosterone Booster, (b) BTH® Human Growth Agent, (c) Zestra® for female arousal and (d) EjectDelay® for premature ejaculation and has an additional five marketed products in this space, including (e) Sensum® for the indication of reduced penile sensitivity, (for sales outside the U.S. only), (f) Zestra Glide®, (g)Vesele® for promoting sexual and cognitive health, (i) Androferti® (in the US and Canada) to support overall male reproductive health and sperm quality, (j) BTH Vision Formula, (k) BTH Blood Sugar, among others and eventually FlutiCare™ OTC for Allergic Rhinitis, if its ANDA is approved by the U.S. FDA.

Business Summary:

Innovus Pharmaceuticals, Inc., a pharmaceutical company, engages in the commercialization, licensing, and development of non-prescription medicine and consumer care products in the United States. Its products include Zestra, a non-medicated patented consumer care product to enhance desire, arousal, and satisfaction in women; EjectDelay, an over-the-counter monograph-compliant benzocaine-based topical gel for treating premature ejaculation; Sensum+, a non-medicated consumer care cream that enhances penile sensitivity; Zestra Glide, a high viscosity and low osmolality water-based lubricant; Vesele, a proprietary oral dietary supplement to enhance nitric oxide beneficial clinical effects on sexual functions and brain health; and Androferti to support overall male reproductive health and sperm quality. The company?s pipeline products includes FlutiCare, an over the counter drug for Rhinitis; Urocis for urinary tract infection; and AndroVit, a proprietary supplement to support overall prostate and male sexual health. The company markets and sells its products through commercial partners to primary care physicians, urologists, gynecologists, and therapists; and directly to consumers through online channels, retailers, and wholesalers. Innovus Pharmaceuticals, Inc. was incorporated in 2011 and is based in San Diego, California.

Bassam Damaj, Ph.D.  President and Chief Executive Officer:                           

Dr. Bassam Damaj was appointed to serve as our President and Chief Executive Officer in January 2013. Prior to joining Innovus Pharma, Dr. Damaj served as President and Chief Executive Officer of Apricus Biosciences, Inc. (NASDAQ: APRI), a specialty pharmaceutical company, from December 2009 until November 2012. At Apricus Bio, Dr. Damaj was responsible for the approval of its lead drug Vitaros, a treatment for erectile dysfunction. Dr. Damaj also signed multimillion dollar partnerships between Apricus Bio and leading pharmaceutical companies such as Abbott, Novartis-Sandoz and Takeda. Before Apricus Bio, Dr. Damaj was a co-founder of Bio-Quant, Inc. and served as the Chief Executive Officer and Chief Scientific Officer and a Director of Bio-Quant's board of directors from its inception in June 2000 until its acquisition by Apricus Biosciences in December 2009. In addition, Dr. Damaj was the founder, Chairman, President and Chief Executive Officer of R&D Healthcare, and the co-founder of Celltek Biotechnologies. He also served as a Director of the Board of Directors at CreAgri, Inc. and was a Member of the Scientific Advisory Board of MicroIslet, Inc. He is the author of the Immunological Reagents and Solutions reference book, the inventor of many patents and author of numerous peer reviewed scientific publications. Dr. Damaj won a US Congressional award for the Anthrax Multiplex Diagnostic Test in 2003. Dr. Damaj holds a Ph.D. degree in Immunology/Microbiology from Laval University and completed a postdoctoral fellowship in molecular oncology from McGill University.

Who are the major players at Innovus Pharma?

Management Team


* Bassam Damaj, Ph.D.

President and Chief Executive Officer

Prior to joining Innovus Pharma, Bassam Damaj served as President and Chief Executive Officer of Apricus Biosciences, Inc. (NASDAQ: APRI), a specialty pharmaceutical company where he was responsible for the approval of its lead drug Vitaros™, a treatment for erectile dysfunction. Damaj also signed multimillion-dollar partnerships between Apricus Bio and leading pharmaceutical companies such as Abbott, Novartis-Sandoz and Takeda. He was also a Co-founder of Bio-Quant, Inc., serving as the Chief Executive Officer/Chief Scientific Officer and managing the board of directors from its inception in June 2000 until its 2009 acquisition by Apricus Biosciences. In addition, Damaj was the Founder/Chairman/President/Chief Executive Officer of R&D Healthcare, and the Co-Founder of Celltek Biotechnologies. He also served as a Director of the Board of Directors at CreAgri, Inc. and was partof the Scientific Advisory Board of MicroIslet, Inc. He authored Immunological Reagents and Solutions: A Laboratory Handbook (2000) and won a U.S. Congressional Award for the Anthrax Multiplex Diagnostic Test in 2003. Damaj holds a Ph.D. degree in Immunology/Microbiology from Laval University and completed a postdoctoral fellowship in Molecular Oncology at McGill University.


* Randy Berholtz, M.B.A./J.D.

Executive Vice President, Corporate Development and General Counsel

In addition to his responsibilities as Executive Vice President and Corporate Development and General Counsel, Randy Berholtz is also the Secretary of the company. He was the founding partner of the Sorrento Valley Law Group and is the former Executive Vice President and General Counsel and Secretary of Apricus Biosciences, Inc. (NASDAQ: APRI), a specialty pharmaceutical company. Prior to that time, he was the Vice President, General Counsel and Secretary of ACON Laboratories, Inc., a group of Chinese and U.S. life sciences companies. He has also been the Chief Operating Officer and General Counsel of IngleWood Ventures, L.P., a life sciences venture capital company, and the Interim General Counsel and Secretary of Nanogen, Inc. (NASDAQ: NGEN), a genomics tools company. He has also been an attorney with the law firms, including Heller Ehrman LLP, Cooley LLP, Kirkpatrick & Lockhart LLP (now K&L Gates LLP) and Cravath, Swaine & Moore LLP. He has a Bachelor of Arts degree from Cornell University, a Master of Arts degree from Oxford University (he was a Rhodes Scholar), and a Juris Doctor degree from Yale Law School - where he was a Senior Editor of the Yale Law Journal - and an MBA from the University of San Diego School of Business.

* Ryan Selhorn, CPA

Vice President, Chief Financial Officer

Ryan has served as our Vice President and Chief Financial Officer since April 27, 2018. From July 2013 to April 2018, he was the Chief Financial Officer and Chief Accounting Officer of Signature Analytics, an outsourced finance and accounting firm. From October 2003 to July 2013, he was an Audit Senior Manager with Grant Thornton LLP, a financial accounting firm. Mr. Selhorn has significant experience with venture financings, public equity offerings, public debt offerings, mergers and acquisitions, interaction with the SEC and PCAOB, and implementation and monitoring compliance with the requirements of the Sarbanes-Oxley Act. Additionally, Mr. Selhorn has participated in several financial due diligence processes for acquisitions and capital financings. Mr. Selhorn received his B.S. in Accounting and Finance from Georgetown University, McDonough School of Business, and he is a certified public accountant in California.

* Christopher Stella

Vice President of Operations

Christopher Stella has served as our Vice President of Operations since June 2018. From February 2014 to June 2018 he was President and CEO of Stella Marketing Group, a specialty marketing firm supporting the natural products industry including major public and private health and beauty companies advertising through various direct-to-consumer channels. One of which, Innovus Pharmaceuticals, where he worked directly with management and helped the company exceed revenue targets in both 2017 and 2018. From September 2013 to February 2014, he worked at Nutraclick, a technology-driven health and wellness products company, where he developed the marketing campaigns for their four leading brands found in both major retail outlets such as GNC, Walmart and CVS and popular ecommerce platforms. Mr. Stella received his Bachelor of Economics from the University of Massachusetts (Suma Cum Laude) at Amherst with minors in both Chinese and Finance from the School.

info@innovuspharma.com  (email)

Share Structure:

Low Floater

Profitability expected exiting 2019 !
- 2018 Projected Revenue of $23M, smashing $8.8M for all of 2017 
- 78%+ Gross Margin

Products for Purchase:




Company Videos:

Innovus Pharma CEO Provides Shareholder Update and Conference Call






Innovus Pharma (INNV): Targeting Multiple Billion Markets With Commercial Products


Prior Accomplishments:





Existing Product Lines @ Innovus Pharma:




PROSTAGORX™ is a clinical strength, multi response prostate supplement, scientifically formulated to effectively maintain good prostate health and help in prevent prostate issues in the future. ProstaGorx™ was developed by top medical doctors and produced in a top-quality, cGMP certified and FDA registered laboratory environment under the most rigorously professional conditions. 

The positive benefits provided by the individual and combination ingredients in ProstaGorx™ have been published in leading medical journals.

- WHAT IS DiabaSens™?______________________________________________________________________________________________________________

DiabaSens™ is a patent-pending advanced, all-natural cream specifically formulated to increase nerve sensation and blood flow in men and women of all ages. Its proprietary blend of key ingredients has been clinically tested to increase sensation of the skin and improve blood flow where applied. DiabaSens™ was developed by top medical researchers and produced in a top-quality, cGMP-certified and FDA-registered laboratory environment under the most rigorously professional conditions. The positive benefits provided by the individual and combination ingredients in DiabaSens™ have been published in leading medical journals.

Are you looking to boost your brain health?r

UriVArx® Bladder Control and Function 

http://www.myandroferti.com/  - (In a dozen CVS "pilot" stores)

https://www.myvesele.com/ - (Better SEX, WOW-Z'ers)


** Help to get the word out and be a PRODUCT AMBASSADOR for YOUR company   

Image result for images of love                    Products ship world-wide - support YOUR company                                                                               



Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
INNV News: Current Report Filing (8-k) 04/19/2019 10:20:08 AM
INNV News: Current Report Filing (8-k) 03/15/2019 05:03:14 PM
INNV News: Current Report Filing (8-k) 02/26/2019 06:13:42 AM
INNV News: Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) 02/13/2019 03:18:41 PM
INNV News: Securities Registration Statement (s-1/a) 02/08/2019 04:58:27 PM
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
#17551  Sticky Note Innovus Pharma Receives Approval from Amazon(R) to Expand florida investor 10/15/18 08:38:36 AM
#20035   I'd also add like there was no tomorrow. jtaylor68 04/21/19 07:49:00 AM
#20034   I hope you are right on this one. Batermere 04/21/19 07:33:23 AM
#20033   Bet this doesnt even move on monday. Totally jbdiver 04/21/19 07:26:34 AM
#20032   If Boyd was Shorting then he will have Batermere 04/20/19 11:02:10 PM
#20031   See, I really think it's bigger than that. Honeycomb777 04/20/19 10:48:36 PM
#20030   Happy Easter Eve, HC. You’ve been busy this Batermere 04/20/19 09:53:07 PM
#20029   Bate - In the spirit of Easter, I Honeycomb777 04/20/19 09:02:41 PM
#20028   Folks, don't forget about this product...I just put Honeycomb777 04/20/19 05:56:07 PM
#20027   Agree on this post mostly. In mulally 04/20/19 05:05:10 PM
#20026   Good post HC. mulally 04/20/19 05:02:48 PM
#20025   If you follow me here, I think you Honeycomb777 04/20/19 01:38:14 PM
#20024   I would strongly encourage newbies to support your Honeycomb777 04/20/19 11:54:00 AM
#20023   INCREDIBLE and FACTUAL STATISTIC: Honeycomb777 04/20/19 11:29:58 AM
#20022   DUH, It most certainly is in the past Batermere 04/20/19 07:48:36 AM
#20021   We’ve been waiting months/years on this ANDA and mulally 04/20/19 06:18:55 AM
#20020   Ya It should go up big Monday for mulally 04/20/19 06:18:05 AM
#20019   Honey is back to being long and a jbdiver 04/20/19 02:46:50 AM
#20018   Time for some math folks: Honeycomb777 04/19/19 05:53:30 PM
#20017   The vast majority of these 1,000 units are jtaylor68 04/19/19 05:48:24 PM
#20016   Want to help...really help your company's bottom line? Honeycomb777 04/19/19 05:27:33 PM
#20015   I am LOL because: Honeycomb777 04/19/19 05:12:21 PM
#20014   BOOYAH! My Target Price is $30. I will Batermere 04/19/19 04:58:00 PM
#20013   LOL - let's be realistic... Say 1000 units Drugdoctor 04/19/19 01:32:30 PM
#20012   Folks - once things really get rolling with Honeycomb777 04/19/19 12:25:34 PM
#20010   You really never heard of aggressive growth that jtaylor68 04/19/19 11:53:03 AM
#20009   No they don't. Look at the numbers from jtaylor68 04/19/19 11:50:36 AM
#20008   A business model that only generates losses and Drugdoctor 04/19/19 11:46:52 AM
#20007   What is flawed is your due diligence and jtaylor68 04/19/19 11:43:21 AM
#20006   re" profitability will happen soon." Same thing Drugdoctor 04/19/19 11:42:27 AM
#20005   Wow, you claim they haven't done anything to jtaylor68 04/19/19 11:41:47 AM
#20004   Sorry but you haven't obviously studied the financial jtaylor68 04/19/19 11:38:18 AM
#20003   All I know for sure is $INNV has Drugdoctor 04/19/19 11:36:38 AM
#20002   Did you ever think Da wanted to ensure Honeycomb777 04/19/19 11:08:15 AM
#20001   Their business model is flawed... Huge sales advertising Drugdoctor 04/19/19 10:40:18 AM
#20000   20,000 post is claimed by me ! Honeycomb777 04/19/19 10:37:16 AM
#19999   And what if they are acquired say 6-7 Honeycomb777 04/19/19 10:36:46 AM
#19998   Well, sadly, the approval comes too late for Drugdoctor 04/19/19 10:33:03 AM
#19997   Just want to say...Boyd thinks he got a Honeycomb777 04/19/19 10:32:15 AM
#19996   DD, respectfully, you are missing the point. Honeycomb777 04/19/19 10:24:10 AM
#19995   $AKRX-got-the-ANDA-for-$INNV's-product, and-this-is-their-situation... Drugdoctor 04/19/19 10:16:06 AM
#19994   If I am Da ( well shat, I Honeycomb777 04/19/19 09:48:47 AM
#19993   And Bert... float is so small here and Honeycomb777 04/19/19 09:33:58 AM
#19992   Bert, Taylor is correct. This was the Honeycomb777 04/19/19 09:30:01 AM
#19991   It's going to be a slightly different formulation jtaylor68 04/19/19 03:36:10 AM
#19990   Margins are better. Damaj had confirmed that. jtaylor68 04/19/19 03:26:33 AM
#19989   Can someone please explain the benefits of "FDA bertbex 04/19/19 03:04:05 AM
#19988   Cool story, Bro. So you like to dwell Batermere 04/19/19 12:32:45 AM
#19986   $AKRX??? LMAO - they are down over 80% Drugdoctor 04/18/19 10:58:31 PM
#19985   Sure hope people are buying this product ? Honeycomb777 04/18/19 10:33:28 PM
#19984   Heck yeah I played Karsten ! State Honeycomb777 04/18/19 09:34:31 PM